Biotechnology

The deal completes insitro’s TherML platform, integrating physics-informed AI to design better drugs faster by solving efficacy and manufacturing hurdles at once.

Juvena Therapeutics lands a $33.5M Series B and a major pharma deal to advance its AI-discovered regenerative drugs for neuromuscular diseases.

LyfeSci's acquisition of Clinically Media aims to fix the clinical trial bottleneck by integrating patient recruitment, promising faster, more diverse studies.

Biotech veteran Kamran Tavangar, who built a multi-billion dollar company at LabCentral, returns to lead its science strategy and shape the future of innovation.

With a new name and a laser focus on its lead hemophilia A drug, Metagenomi Therapeutics signals a major shift from platform tech to clinical powerhouse.

Following a successful three-year transformation, B-FLEXION acquires full ownership of Radius Health, betting big on its blockbuster osteoporosis drug TYMLOS®.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

ConcertAI and Foundation Medicine unite to create a huge dataset of 500k patients, using AI to accelerate the hunt for new life-saving cancer drugs.

Cogent Biosciences is set for a transformative year, eyeing three FDA submissions and a launch for its lead drug, with a deep pipeline to follow.

FDA clears a novel two-part immunotherapy that paints solid tumors with a synthetic target, unleashing a powerful CAR T-cell attack in a new clinical trial.

Promising new 96-week data shows Vir's therapy could redefine care for severe hepatitis delta, as its oncology pipeline and financial runway also advance.

AbbVie inks a massive deal for a novel bispecific antibody, aiming to combine it with ADCs and enter the high-stakes race for solid tumor therapies.

With preliminary Q1 revenue of $103.7M, Twist Bioscience beats forecasts, setting a bullish tone ahead of its full earnings report on February 2nd.

Biomea Fusion launches a high-stakes 2026 plan, advancing a novel diabetes drug to restore insulin cells and an oral pill to rival obesity giants.

Backed by Purolator, a massive network expansion by Williams Pharmalogistics aims to reshape Canada's temperature-controlled medical delivery landscape.

TriSalus Life Sciences reports record 53% annual revenue growth, but a closer look reveals a complex financial picture for the oncology innovator.

With its new thalassemia drug AQVESME launching, Agios aims for blockbuster status while navigating a key safety warning and advancing a broad pipeline.

Adaptive posted a 55% revenue surge in 2025, fueled by its clonoSEQ cancer test. Now, the firm is charting a clear course to company-wide profitability.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

As a foundational CFO steps down, XOMA Royalty brings in biotech veteran Jeffrey Trigilio to enhance its dealmaking strategy and expand its royalty portfolio.